NVO Stock Discussion (Novo Nordisk A S)

Novo licenses early-stage weekly obesity pill for $300 million upfront

Novo Nordisk ($NVO) has agreed to license Hengrui Pharma’s HRS-1596, an experimental oral medicine targeting both GLP-1 and GIP receptors. The agreement includes $300 million upfront within a potential $2.6 billion total, with the balance dependent on development, regulatory and commercial milestones. Hengrui would also receive sales royalties. Novo’s exclusive territory excludes mainland China, Hong Kong, Macao and Taiwan. The candidate could expand Novo’s obesity and diabetes pipeline with a o

NVO

@tickerstat1 month ago

Novo Nordisk sets new pipeline and manufacturing ambitions

Novo Nordisk ($NVO) outlined ambitions to launch more than five major new medicines by 2030 and generate over DKK150 billion in risk-adjusted sales from its current pipeline by 2035. It also intends to enter or complete at least five Phase 3 programs in obesity and diabetes and at least five in other therapeutic areas. The manufacturing plan calls for capacity to serve ten times more people with oral GLP-1 obesity treatments, while the broader group aims to reach more than 60 million patients by

NVO

@tickerstat1 month ago

Novo’s weekly growth-hormone treatment gains another European recommendation

Novo Nordisk ($NVO) received a positive European advisory opinion for once-weekly Sogroya in children with idiopathic short stature and persistent growth disturbance. The proposed expansion is supported by the REAL8 study, which found the weekly treatment non-inferior to daily growth-hormone therapy on height velocity after 52 weeks. The recommendation follows earlier positive opinions covering children born small for gestational age and those with Noonan syndrome. Novo expects European Commissi

NVO

@tickerstat1 month ago

Novo Nordisk receives positive European opinion for hemophilia treatment

Novo Nordisk ($NVO) received a positive recommendation from the European Medicines Agency’s human medicines committee for FREHEMGO, its denecimig treatment for hemophilia A. The proposed indication covers adults and children, including patients with and without inhibitors. The medicine would be delivered by a prefilled pen under the skin, with weekly, every-two-week or monthly dosing options. The recommendation draws on the FRONTIER development program, which showed reductions in bleeding compar

NVO

@tickerstat1 month ago

Novo Nordisk reports positive STEP Young results in children aged 6 to under 12

Novo Nordisk announced first STEP Young Phase 3 results on 7 September 2026. Trial design and outcome The randomised, double-blind study involved 165 children aged 6 to under 12, comparing weekly semaglutide with placebo. Both groups received diet and physical-activity support. The trial met its primary endpoint of superior BMI reduction after 68 weeks. The company reports that 40.4% of semaglutide-treated participants fell below the childhood-obesity threshold, compared with 0% on placebo. That